YTHDF2 in peritumoral hepatocytes mediates chemotherapy-induced antitumor immune responses through CX3CL1-mediated CD8+ T cell recruitment by Zhenyun Yang, Xin Wang, Yizhen Fu, Weijie Wu, Zili Hu, Qingyang Lin, Wei Peng, Yangxun Pan, Juncheng Wang, Jinbin Chen, Dandan Hu, Zhongguo Zhou, Li Xu, Yaojun Zhang, Jiajie Hou, Minshan Chen

“…Additionally, YTHDF2 mediated the response to immunotherapy. Mechanistically, OXA upregulated YTHDF2 expression by activating the cGAS-STING signaling pathway and consequently enhanced the therapeutic outcomes of immunotherapeutic interventions. …”
Get full text

Ferroptosis: A novel cell death modality as a synergistic therapeutic strategy with photodynamic therapy by Yuqing Wang, Yiting Xu, Yong Qu, Yifang Jin, Juanmei Cao, Jinshan Zhan, Zhuoxia Li, Chuxing Chai, Changzheng Huang, Min Li

“…Hence, the development of precisely targeted tumor therapies and exploration of immunotherapy represent additional strategies for tumor treatment. …”
Get full text

Plasma S100A8/A9 level predicts response to immune checkpoint inhibitors in patients with advanced non-small cell lung cancer by Tadahiro Kuribayashi, Rie Kinoshita, Kiichiro Ninomiya, Go Makimoto, Toshio Kubo, Kammei Rai, Eiki Ichihara, Katsuyuki Hotta, Masahiro Tabata, Yoshinobu Maeda, Katsuyuki Kiura, Shinichi Toyooka, Masakiyo Sakaguchi, Kadoaki Ohashi

“…We investigated the association of the plasma level of S100A8/A9 with the efficacy of immunotherapy. We evaluated patients with unresectable stage III/IV or recurrent non-small cell lung cancer (NSCLC) who were treated with ICIs at Okayama University Hospital. …”
Get full text

MicroRNA-3145 as a potential therapeutic target for hepatitis B virus: inhibition of viral replication via downregulation of HBS and HBX by Amrizal Muchtar, Amrizal Muchtar, Daichi Onomura, Daichi Onomura, Dan Ding, Dan Ding, Hironori Nishitsuji, Kunitada Shimotohno, Shunpei Okada, Keiji Ueda, Koichi Watashi, Takaji Wakita, Kei Iida, Kei Iida, Hironori Yoshiyama, Hisashi Iizasa

Get full text

Identification of a distinctive immunogenomic gene signature in stage-matched colorectal cancer by Pankaj Ahluwalia, Ashis K. Mondal, Ashutosh Vashisht, Harmanpreet Singh, Ahmet Alptekin, Kalyani Ballur, Nivin Omar, Meenakshi Ahluwalia, Kimya Jones, Amanda Barrett, Vamsi Kota, Ravindra Kolhe

“…Despite advances in diagnosis and treatment, including surgery, chemotherapy, and immunotherapy, accurate clinical markers are still lacking. …”
Get full text

Hepatocellular carcinoma: signaling pathways and therapeutic advances by Jiaojiao Zheng, Siying Wang, Lei Xia, Zhen Sun, Kui Ming Chan, René Bernards, Wenxin Qin, Jinhong Chen, Qiang Xia, Haojie Jin

“…New trials are investigating combination therapies involving ICIs and TKIs or anti-VEGF (endothelial growth factor) therapies, as well as combinations of two immunotherapy regimens. The outcomes of these trials are expected to revolutionize HCC management across all stages. …”
Get full text

Intravenous versus subcutaneous tocilizumab in Takayasu arteritis: multicentre retrospective study by Patrice Cacoub, Arsène Mekinian, David Saadoun, Pavel I Novikov, Savino Sciascia, Corrado Campochiaro, Olivier Fain, Ilya Smitienko, Nicolas Schleinitz, Patrick Jégo, Francesco Muratore, Carlo Salvarani, Elena Galli, Sabine Berthier, Marc Lambert, François Maurier, Isabelle Kone-Paut, Sergey Moiseev, Masataka Kuwana, Alexandre Belot, Martin Michaud, Francis Gaches, Achille Aouba, Xavier Puechal, Karim Sacre, Tiphaine Goulenok, Alessandro Tomelleri, Thomas Sené, Elena Marina Baldissera, Luigi Boiardi, Abid Awisat, Ygal Benhamou, Vahan Mukuchyan, Mathieu Vautier, Azeddine Dellal, Lucie Biard, Julie Seguier, José Hernández-Rodríguez, Olivier Espitia, Sebastien Humbert, Guillaume Denis, Nolan Hassold, Dagna Lorenzo, Helene Munoz Pons, Jean Baptiste Gaultier, Le Mouel Edwige, Antoinette Perlat, Bertrand Lioger, Jonathan Broner, Virginie Dufrost, Faten Frikha, Alexandra Audemard-Verger, Pascal Woaye-Hune, Pierre Zeminsky, Moya Alvarado, Matheus Vieira, Alberto Lo Gullo

Get full text

LncRNAs in serum-derived extracellular vesicles are potential biomarker and correlated with immune infiltration in gastric cancer by Juan Ding, Yunyan Teng, Rongshu Cui, Jin Liu, Ke Xiao, Zhaogang Dong, Yi Zhang, Xiaofei Xu

“…It provides a foundation for the development of serum EV-targeted novel biomarkers and immunotherapy targets of GC.…”
Get full text

Immune infiltration landscape and potential drug-targeted implications for hepatocellular carcinoma with ‘progression/hyper-progression’ recurrence by Jing-Xuan Xu, Yue-Xiang Su, Yuan-Yuan Chen, Yi-Yue Huang, Zu-Shun Chen, Yu-Chong Peng, Lu-Nan Qi

“…Virtual docking was used to identify potential therapeutic targets, and the results were verified using single-nuclei RNA sequencing and histological analysis.Results ITM was closely related to type III–IV recurrence and exhibited immunotherapy potential. The potential efficacy of inhibiting CCNA2, VEGFA, CXCL8, PLK2, TIMP1, ITGB2, ALDOA, ANXA5 and CSK in ITM reversal was determined. …”
Get full text

CC-96673 (BMS-986358), an affinity-tuned anti-CD47 and CD20 bispecific antibody with fully functional fc, selectively targets and depletes non-Hodgkin’s lymphoma by Dan Zhu, Haralambos Hadjivassiliou, Catherine Jennings, David Mikolon, Massimo Ammirante, Sharmistha Acharya, Jon Lloyd, Mahan Abbasian, Rama Krishna Narla, Joseph R. Piccotti, Katie Stamp, Ho Cho, Kandasamy Hariharan

“…The CD47-SIRPα axis has become an important target for cancer immunotherapy. To date, the advancement of CD47-targeted modalities is hindered by the ubiquitous expression of the target, often leading to rapid drug elimination and hematologic toxicity including anemia. …”
Get full text

Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes in Advanced Melanoma Patients by Mélanie Saint-Jean, Anne-Chantal Knol, Christelle Volteau, Gaëlle Quéreux, Lucie Peuvrel, Anabelle Brocard, Marie-Christine Pandolfino, Soraya Saiagh, Jean-Michel Nguyen, Christophe Bedane, Nicole Basset-Seguin, Amir Khammari, Brigitte Dréno

“…Immunotherapy for melanoma includes adoptive cell therapy with autologous tumor-infiltrating lymphocytes (TILs). …”
Get full text

A prognostic signature of Glutathione metabolism-associated long non-coding RNAs for lung adenocarcinoma with immune microenvironment insights by Junxi Hu, Junxi Hu, Shuyu Tian, Shuyu Tian, Qingwen Liu, Qingwen Liu, Jiaqi Hou, Jiaqi Hou, Jun wu, Jun wu, Xiaolin Wang, Xiaolin Wang, Yusheng Shu, Yusheng Shu

“…High-risk patients showed increased tumor mutation burden (TMB) and stemness, emphasizing the potential of personalized immunotherapy to improve survival outcomes.…”
Get full text

Autoimmune brainstem encephalitis: Clinical associations, outcomes, and proposed diagnostic criteria by Michael Gilligan, Smathorn Thakolwiboon, Emma Orozco, Samantha Banks, Eoin P. Flanagan, Sebastian Lopez‐Chiriboga, Jan‐Mendelt Tillema, John R. Mills, Sean J. Pittock, Cristina Valencia Sanchez, Anastasia Zekeridou, Divyanshu Dubey, Andrew McKeon

“…Kaplan–Meier analysis revealed faster progression to wheelchair in patients who were immunotherapy refractory and with elevated CSF IgG index. …”
Get full text

IDH-mutant gliomas in children and adolescents - from biology to clinical trials by Louise Evans, Sarah Trinder, Sarah Trinder, Andrew Dodgshun, Andrew Dodgshun, David D. Eisenstat, David D. Eisenstat, David D. Eisenstat, James R. Whittle, James R. Whittle, James R. Whittle, Jordan R. Hansford, Jordan R. Hansford, Jordan R. Hansford, Santosh Valvi, Santosh Valvi, Santosh Valvi

“…Given the paucity of clinical trial data from pediatric patients with mIDH glioma, we propose guidelines for the inclusion of pediatric and AYA patients with gliomas onto prospective trials and expanded access programs as well as the potential of combined mIDH inhibition and immunotherapy in the treatment of patients with PMMRDIA at high risk of progression.…”
Get full text

Characterizing immune biomarkers and effector CD8+ T-cell exhaustion in pancreatic adenocarcinoma via single-cell RNA sequencing profiling by Rawaa AlChalabi, Raghda Makia, Semaa A. Shaban, Ahmed AbdulJabbar Suleiman

“…This exhaustion, driven by persistent immunosuppressive signals in the tumor microenvironment, impairs immune function and hinders effective immunotherapy. This study aimed to identify key exhaustion-related marker genes in CD8+ T-cells linked to PDAC and assess the potential of repurposing anti-inflammatory drugs to counteract T-cell exhaustion and enhance immune responses against PDAC. …”
Get full text

Medicarpin suppresses lung cancer cell growth in vitro and in vivo by inducing cell apoptosis by Shen Zongyi, Yin Liqi, Chang Manxia, Wang Haifeng, Hao Mingxuan, Liang Youfeng, Guo Rui, Bi Ying, Wang Jiansong, Yu Changyuan, Li Jinmei, Zhai Qiongli, Cheng Runfen, Zhang Jinku, Sun Jirui, Yang Zhao

“…Surgery, chemoradiotherapy, targeted therapy, and immunotherapy are considered dominant treatment strategies for LC in the clinic. …”
Get full text

Unleashing the potential of a low CpG Passer transposon for superior CAR-T cell therapy by Jianyao Zeng, Yan Sun, Yan Sun, Yuan Fang, Xiaodie Wang, Qian Huang, Pingjing Zhang, Meiqi Shao, Pei Wang, Jingbo Cheng, Meng Di, Tao Liu, Qijun Qian, Qijun Qian, Qijun Qian

“…BackgroundTo date, the non-viral vector Chimeric Antigen Receptor (CAR) T cell preparation platform, exemplified by transposons, has demonstrated significant potential in tumor immunotherapy and yielded positive results in multiple clinical trials. …”
Get full text

Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients by Ovidiu Balacescu, Loredana Balacescu, Oana Virtic, Simona Visan, Claudia Gherman, Flaviu Drigla, Laura Pop, Gabriela Bolba-Morar, Carmen Lisencu, Bogdan Fetica, Oana Tudoran, Ioana Berindan-Neagoe

“…Overall, our data indicate that the presence of triple-negative breast cancer is associated with an enrichment of altered systemic immune-related pathways, suggesting that immunotherapy could possibly be synergistic to the chemotherapy, to improve the clinical outcome of these patients.…”
Get full text

Ddx21 mutant peptide is an effective neoantigen in prophylactic lung cancer vaccines and activates long-term anti-tumor immunity by Zhe Zhang, Yimeng Xia, Yimeng Xia, Zhihong Wang, Yaxing Sun, Dan Pu, Yijia He, Ruixian Liu, Yanru Zhang, Yan Liu, Junzhi Yu, Shiyang Ning, Baisui Feng, Yaohe Wang, Na Wang

“…DiscussionThese results suggest that the Ddx21MT is a highly effective neoantigen that can activate anti-tumor immunity, which can serve as an important component in developing a lung cancer vaccine and is expected to be used in combination with other immunotherapy approaches.…”
Get full text

Thymus ad astra, or spaceflight-induced thymic involution by Wataru Muramatsu, Wataru Muramatsu, Maria Maryanovich, Maria Maryanovich, Maria Maryanovich, Taishin Akiyama, Taishin Akiyama, George S. Karagiannis, George S. Karagiannis, George S. Karagiannis, George S. Karagiannis, George S. Karagiannis, George S. Karagiannis

Get full text